A universal sequence to increase protein production

Research

Efficiency of recombinant protein production is an important bottleneck in most biopharmaceutical and biotechnology industries. iPLUS is a new 28-nucleotide noncoding sequence, which can be widely used as an effective tool to boost recombinant protein production.

Aim

  • To incorporate iPLUS in the production of proteins with biotechnology and biopharmaceutical interests to increase efficiency and reduce production costs.

Problem to Solve

The majority of commercial recombinant proteins are produced in mammalian cells but large-scale cell culture requires large volumes of media, making production very expensive.

One of the main requirements is that the target proteins are expressed at very high levels. However, yield is currently limited to 5-10 g/L and takes 10-20 days per batch. With the approval of an increasing number of biopharmaceuticals, the need for more efficient production of recombinant proteins is growing.

Innovation

iPLUS is a new 28-nucleotide noncoding sequence (TRL3-4), which can be widely used as an effective tool to further increase recombinant protein production. iPLUS is innovative because it is very short, therefore it can be incorporated in the target vector without significantly changing its size. Additionally, it is “universal” and compatible with different expression systems (insect, mammalian, etc.). Most importantly, being a non-coding sequence, it does not interfere with the coding sequence, thus avoiding additional regulatory steps and the risk of collateral regulatory effects.

Team

Project Leader

Alexandra Moreira

Instituto de Investigação e Inovação da Universidade do Porto

Project leader

Recombinant DNA Technology Expert

Isabel Pereira-Castro

Instituto de Investigação e Inovação da Universidade do Porto

Biotechnology Engineer

Ana de Jesus

Instituto de Investigação e Inovação da Universidade do Porto

Business Development

Hugo Prazeres

Instituto de Investigação e Inovação da Universidade do Porto

MENTOR

Founder & CSO

Tamara Maes

Oryzon Genomics

Partners

Obra social “la Caixa”
Caixa Capital Risc
Validate-19

Scientific Area

Biochemistry and Molecular biology

Business area

Medical Devices

Research center

Instituto de Investigação e Inovação em Saúde